Filing and reporting period
Important issuer mismatch: The filing provided is Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), not Palvella Therapeutics, Inc. It is a Form 10-K for the fiscal year ended December 31, 2022, filed March 31, 2023; it is not a quarterly report.
Pieris is a clinical-stage biotechnology company developing Anticalin protein therapeutics. It had no approved products and no product-sales revenue; reported revenue came from collaboration and license agreements.
Financial performance and liquidity
Amounts below are in U.S. dollars; financial statement figures are in millions unless stated otherwise.
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $25.9 | $31.4 |
| Research and development expense | $53.0 | $66.7 |
| General and administrative expense | $16.4 | $16.6 |
| Operating loss | $(43.5) | $(51.8) |
| Net loss | $(33.3) | $(45.7) |
| Net loss per share, basic and diluted | $(0.45) | $(0.71) |
| Cash used in operating activities | $(59.9) | $(7.7) |
Revenue fell $5.5 million, or about 18%. R&D expense declined $13.7 million, principally because of lower immuno-oncology spending after the cinrebafusp alfa program was deprioritized, and lower respiratory-program costs. Net loss narrowed by $12.5 million, aided by lower operating expenses and higher grant and interest income. The company reported no income tax benefit. Profit margins are not meaningful for this loss-making, pre-commercial business.
At December 31, 2022, cash and cash equivalents were $38.6 million and short-term investments were $20.5 million, totaling $59.2 million. Current assets were $73.4 million and current liabilities $36.6 million. Total liabilities were $67.6 million, including $13.1 million of operating lease liabilities; the balance sheet shows no conventional borrowings line. Stockholders’ equity was $27.9 million, and accumulated deficit was $290.4 million.
Cash and cash equivalents declined $79.1 million during 2022. Investing cash use of $21.2 million primarily reflected purchases of investments, while financing provided $7.2 million, mainly from ATM share sales. The company sold 2.1 million shares through its ATM for gross proceeds of $7.2 million during 2022.
Business developments and outlook
- Elarekibep: AstraZeneca’s Phase 2a asthma study continued. In 2022, AstraZeneca narrowed the planned efficacy readout to the 3 mg cohort, stopped enrollment in the 1 mg cohort, and dropped the planned 10 mg efficacy cohort. Topline results were expected by mid-2024. Pieris retains specified co-development and U.S. co-commercialization options.
- PRS-220: Pieris dosed the first subject in a Phase 1 inhaled study for pulmonary fibrosis in Australia in the fourth quarter of 2022. The company expected topline results in 2023. A Bavarian government grant supports qualifying development costs through August 2023.
- PRS-344/S095012: The Servier-partnered PD-L1/4-1BB immuno-oncology candidate was in a Phase 1/2 study; Pieris planned to present dose-escalation data in 2023.
- Portfolio changes: Pieris ceased further enrollment in the cinrebafusp alfa Phase 2 study in August 2022 to prioritize resources. Servier discontinued PRS-352/S095025 in December 2022. Pieris and AstraZeneca also discontinued discovery-stage programs; two AstraZeneca discovery programs remained active at year-end.
- Partnered programs: Seagen’s SGN-BB228 entered a sponsored Phase 1 study in January 2023, triggering a $5.0 million milestone. This is a subsequent-period development; the filing says the milestone was recognized as 2022 revenue because the relevant recognition constraint was considered cleared by year-end. Boston Pharmaceuticals was advancing licensed PRS-342/BOS-342 toward Phase 1.
Funding and going concern: Management stated that the company would need additional capital over the next year to maintain its then-current level of activity. Without new funding or spending reductions, the conditions raised substantial doubt about its ability to continue as a going concern. Management nevertheless believed available funds, together with actions within its control and its approved 2023 budget, would fund limited operations for at least 12 months from the filing’s issuance. The plan prioritized obtaining elarekibep Phase 2a data and allowed management to gate future PRS-220 and PRS-400 investment. No assurance of additional financing was given.
The filing reports no material legal proceedings. Management assessed disclosure controls and internal control over financial reporting as effective at December 31, 2022; the auditor did not express an opinion on internal control effectiveness.
Most important facts for investors to verify
- Confirm the issuer: this filing is for Pieris Pharmaceuticals, Inc. (PIRS), not Palvella Therapeutics.
- Check current cash, investment balances, subsequent financing, and any later going-concern disclosures; the filing’s runway statement depends on limited operations and management actions.
- Track elarekibep’s Phase 2a timing, 3 mg efficacy results, and Pieris’s co-development or commercialization election.
- Review 2022 operating cash burn against the $59.2 million year-end cash-and-investments balance, including the effect of collaboration revenue recognition and working-capital movements.
- Verify dilution and remaining ATM capacity, as well as potential future milestone and royalty receipts, which depend on partner decisions and clinical, regulatory, and commercial progress.